Equities

Kaken Pharmaceutical Co Ltd

Kaken Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)4,330.00
  • Today's Change-52.00 / -1.19%
  • Shares traded280.00k
  • 1 Year change+30.19%
  • Beta0.4471
Data delayed at least 20 minutes, as of Nov 26 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Income statement Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
REVENUE AND GROSS PROFIT
Total revenue72,04472,98476,034
OPERATING EXPENSES
Cost of revenue total33,50533,42834,458
Selling, general and admin. expenses, total16,16515,47615,833
Depreciation/amortization317291258
Unusual expense(income)1671,9123,860
Other operating expenses, total1.002.001.00
Total operating expense62,69866,89862,830
Operating income9,3466,08613,204
Other, net55335137
INCOME TAXES, MINORITY INTEREST AND EXTRA ITEMS
Net income before taxes9,7966,81713,885
Provision for income taxes1,7701,3774,336
Net income after taxes8,0265,4409,549
Minority interest------
Net income before extra. Items8,0265,4409,549
Total extraordinary items------
Net income8,0265,4409,549
Inc.avail. to common excl. extra. Items8,0255,4409,549
Inc.avail. to common incl. extra. Items8,0255,4409,549
EPS RECONCILIATION
Basic/primary weighted average shares383838
Basic/primary eps excl. extra items213145251
Basic/primary eps incl. extra items213145251
Dilution adjustment------
Diluted weighted average shares383838
Diluted eps excl. extra items213145251
Diluted eps incl. extra items213145251
COMMON STOCK DIVIDENDS
DPS - common stock primary issue150150150
Gross dividend - common stock5,6845,6245,678
PRO FORMA INCOME
Pro forma net income------
Interest expense, supplemental171717
SUPPLEMENTAL INCOME
Depreciation, supplemental2,5962,5462,481
Total special items3241,9333,670
NORMALISED INCOME
Normalized income before taxes10,1208,75017,555
Effect of special items on income taxes303861,145
Income tax excluding impact of special items1,8001,7635,481
Normalized income after tax8,3206,98712,074
Normalized income avail. to common8,3196,98712,074
Basic normalized EPS220186318
Diluted normalized EPS220186318
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.